Search research articles
Contact Us
Filters
Showing results (11-20 of 174) with videos related to
Page
of 18
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
May 29, 2018
Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies
Alex F Herrera, Arturo Molina
Therapeutic Advances in Hematology
|
September 14, 2018
Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
Sarah Tomassetti, Alex F Herrera
Blood
|
May 25, 2023
The next frontier: enter PD-1 and exit PET scans?
Matthew Mei, Alex F Herrera
Hematology. American Society of Hematology. Education Program
|
December 9, 2022
Incorporating novel agents into frontline treatment of Hodgkin lymphoma
Swetha Kambhampati Thiruvengadam, Alex F Herrera
Hematology/Oncology Clinics of North America
|
February 10, 2026
New Tools and Drugs Improve the Balance Between Cure and Toxicity in Hodgkin Lymphoma
Alex F Herrera, Alison J Moskowitz
Blood Advances
|
September 9, 2025
Multifaceted cfDNA profiling in mantle cell lymphoma
Brian J Sworder, Alex F Herrera
Blood
|
March 30, 2019
CAR T cells mimicking an aggressive lymphoma
Joo Y Song, Alex F Herrera
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2014
Ibrutinib for the treatment of mantle cell lymphoma
Alex F Herrera, Eric D Jacobsen
Haematologica
|
April 6, 2023
Can we cure relapsed/refractory Hodgkin lymphoma without a stem cell transplant?
Matthew G Mei, Alex F Herrera
Current Hematologic Malignancy Reports
|
August 24, 2018
Updates on Circulating Tumor DNA Assessment in Lymphoma
Justin M Darrah, Alex F Herrera
Page
of 18
Search research articles
Search
Showing results (11-20 of 174) with videos related to
Sort By:
Page
of 18
Clinical Lymphoma, Myeloma & Leukemia
|
May 29, 2018
Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies
Alex F Herrera, Arturo Molina
Therapeutic Advances in Hematology
|
September 14, 2018
Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
Sarah Tomassetti, Alex F Herrera
Blood
|
May 25, 2023
The next frontier: enter PD-1 and exit PET scans?
Matthew Mei, Alex F Herrera
Hematology. American Society of Hematology. Education Program
|
December 9, 2022
Incorporating novel agents into frontline treatment of Hodgkin lymphoma
Swetha Kambhampati Thiruvengadam, Alex F Herrera
Hematology/Oncology Clinics of North America
|
February 10, 2026
New Tools and Drugs Improve the Balance Between Cure and Toxicity in Hodgkin Lymphoma
Alex F Herrera, Alison J Moskowitz
Blood Advances
|
September 9, 2025
Multifaceted cfDNA profiling in mantle cell lymphoma
Brian J Sworder, Alex F Herrera
Blood
|
March 30, 2019
CAR T cells mimicking an aggressive lymphoma
Joo Y Song, Alex F Herrera
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2014
Ibrutinib for the treatment of mantle cell lymphoma
Alex F Herrera, Eric D Jacobsen
Haematologica
|
April 6, 2023
Can we cure relapsed/refractory Hodgkin lymphoma without a stem cell transplant?
Matthew G Mei, Alex F Herrera
Current Hematologic Malignancy Reports
|
August 24, 2018
Updates on Circulating Tumor DNA Assessment in Lymphoma
Justin M Darrah, Alex F Herrera
Page
of 18